Biosimilar Antibodies
Codrituzumab Biosimilar – Anti-GPC3 mAb – Research Grade, ProteoGenix, PX-TA1325
Description of Codrituzumab Biosimilar - Anti-GPC3 mAb - Research Grade General information on Anti-GPC3[Homo sapiens] (Codrituzumab) Monoclonal Antibody Codrituzumab is investigated for the treatment of Advanced or Metastatic Hepatocellular Carcinoma.
Host
Reactivity
Applications
Conjugation
Coltuximab Biosimilar – Anti-CD19 mAb – Research Grade, ProteoGenix, PX-TA1345
Description of Coltuximab Biosimilar - Anti-CD19 mAb - Research Grade General information on Anti-CD19 [Homo sapiens] (Coltuximab) Monoclonal Antibody Coltuximab ravtansine is directed against CD19 and is investigated to treat acute lymphoblastic leukemia.
Host
Reactivity
Applications
Conjugation
Conbercept Biosimilar – Anti-VEGFA fusion protein – Research Grade, ProteoGenix, PX-TA2007
Description of Conbercept Biosimilar - Anti-VEGFA fusion protein - Research Grade Introduction Conbercept Biosimilar is a research grade anti-VEGFA fusion protein that has shown promising results in the treatment of various diseases. This novel therapeutic agent is derived from the fusion of two anti-VEGFA antibodies, making it a unique and powerful treatment option for diseases associated with abnormal angiogenesis. Structure of Conbercept Biosimilar Conbercept Biosimilar is a fusion protein composed of two distinct anti-VEGFA antibodies, each with a different binding affinity and specificity towards VEGFA. The first antibody, derived from the humanized monoclonal antibody bevacizumab, binds to the VEGFA receptor and inhibits its activity. The second antibody, derived from the monoclonal antibody ranibizumab, binds to the VEGFA ligand and prevents its interaction with the receptor. This dual mechanism of action makes Conbercept Biosimilar a potent inhibitor of VEGFA signaling. Activity of Conbercept Biosimilar The main activity of Conbercept Biosimilar is its ability to inhibit VEGFA signaling. VEGFA is a key mediator of angiogenesis, the process by which new blood vessels are formed. This process is essential for tissue growth and repair, but it can also contribute to the development of diseases such as cancer, age-related macular degeneration, and diabetic retinopathy. By blocking VEGFA signaling, Conbercept Biosimilar can effectively inhibit the growth of new blood vessels, thereby preventing the progression of these diseases. Application of Conbercept Biosimilar Conbercept Biosimilar has shown promising results in the treatment of various diseases associated with abnormal angiogenesis. Its main application is in the treatment of neovascular age-related macular degeneration (nAMD), a leading cause of blindness in the elderly population. In clinical trials, Conbercept Biosimilar has demonstrated superior efficacy compared to other anti-VEGFA therapies, with a longer duration of action and fewer injections required. In addition to nAMD, Conbercept Biosimilar has also shown potential in the treatment of diabetic macular edema (DME) and diabetic retinopathy. These conditions are characterized by abnormal angiogenesis in the retina, leading to vision loss. By inhibiting VEGFA signaling, Conbercept Biosimilar can reduce the leakage of blood and fluid into the retina, improving vision and preventing further damage. Furthermore, Conbercept Biosimilar has also been investigated as a potential treatment for various cancers, including colorectal, lung, and breast cancer. VEGFA is known to play a crucial role in tumor growth and metastasis, and by targeting this pathway, Conbercept Biosimilar has the potential to slow down or even halt the progression of these cancers. Conclusion In summary, Conbercept Biosimilar is a novel anti-VEGFA fusion protein that has shown promising results in the treatment of various diseases associated with abnormal angiogenesis. Its unique structure and dual mechanism of action make it a potent inhibitor of VEGFA signaling, making it a promising therapeutic option for a wide range of diseases. Further research and clinical trials are needed to fully explore the potential of Conbercept Biosimilar in the treatment of these diseases.
Host
Reactivity
Applications
Conjugation
Crovalimab Biosimilar – Anti-C5 mAb – Research Grade, ProteoGenix, PX-TA1497
Description of Crovalimab Biosimilar - Anti-C5 mAb - Research Grade The Structure of Crovalimab Biosimilar Crovalimab Biosimilar, also known as Anti-C5 mAb, is a monoclonal antibody that targets the complement protein C5. This biosimilar is a highly specific and potent antibody that is designed to mimic the structure and function of the original drug, eculizumab. Crovalimab Biosimilar is a research grade antibody that is currently being developed for the treatment of various complement-mediated diseases. Structure of Crovalimab Biosimilar Crovalimab Biosimilar is a recombinant humanized IgG2/4κ monoclonal antibody. It is composed of two heavy chains and two light chains, each containing a variable region and a constant region. The variable region of the antibody is responsible for binding to the target protein, C5. The constant region of the antibody is responsible for mediating various effector functions, such as complement activation and antibody-dependent cellular cytotoxicity (ADCC). Mechanism of Action Crovalimab Biosimilar works by binding to the complement protein C5 and preventing its cleavage into C5a and C5b. This cleavage is a crucial step in the activation of the complement cascade, which is involved in various inflammatory and immune responses. By inhibiting the cleavage of C5, Crovalimab Biosimilar effectively blocks the downstream effects of the complement cascade, leading to a decrease in inflammation and tissue damage. Therapeutic Applications Crovalimab Biosimilar is being developed for the treatment of various complement-mediated diseases, including paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and myasthenia gravis. These diseases are characterized by an overactive complement system, leading to tissue damage and organ dysfunction. By targeting C5, Crovalimab Biosimilar has the potential to provide a targeted and effective treatment for these diseases. Benefits of Crovalimab Biosimilar As a research grade antibody, Crovalimab Biosimilar offers several benefits over the original drug, eculizumab. Firstly, it is a more cost-effective option, making it more accessible for patients and healthcare systems. Additionally, being a biosimilar, it has been extensively tested for safety and efficacy, providing reassurance to both patients and healthcare providers. Finally, Crovalimab Biosimilar has the potential to improve patient outcomes by providing a targeted and effective treatment option for complement-mediated diseases. Conclusion In summary, Crovalimab Biosimilar is a highly specific and potent monoclonal antibody that targets the complement protein C5. Its unique structure and mechanism of action make it a promising treatment option for various complement-mediated diseases. As a research grade antibody, it offers several benefits over the original drug, making it a more accessible and cost-effective option for patients. With ongoing research and development, Crovalimab Biosimilar has the potential to improve the lives of patients suffering from complement-mediated diseases.
Host
Reactivity
Applications
Conjugation
Cudarolimab Biosimilar – Anti-TNFRSF4 mAb – Research Grade, ProteoGenix, PX-TA1651
Description of Cudarolimab Biosimilar - Anti-TNFRSF4 mAb - Research Grade Introduction to Cudarolimab Biosimilar Cudarolimab Biosimilar is a monoclonal antibody (mAb) that targets and inhibits the activity of tumor necrosis factor receptor superfamily member 4 (TNFRSF4), also known as OX40. It is a biosimilar version of Cudarolimab, a therapeutic antibody currently in clinical development for the treatment of various cancers. Structure of Cudarolimab Biosimilar Cudarolimab Biosimilar is a recombinant humanized IgG1 mAb, with a molecular weight of approximately 148 kDa. It is composed of two heavy chains and two light chains, each containing a variable region and a constant region. The variable region of the antibody is responsible for binding to TNFRSF4, while the constant region plays a role in immune effector functions. Activity of Cudarolimab Biosimilar TNFRSF4 is a co-stimulatory molecule that is expressed on the surface of activated T cells. It plays a critical role in regulating T cell activation and survival, and its dysregulation has been implicated in the development and progression of various cancers. Cudarolimab Biosimilar binds to TNFRSF4 and blocks its interaction with its ligand, OX40L, thereby inhibiting downstream signaling pathways that promote T cell proliferation and survival. In addition to its direct effect on T cells, Cudarolimab Biosimilar also has an indirect anti-tumor activity through its ability to modulate the tumor microenvironment. By blocking TNFRSF4 signaling, the antibody can inhibit the recruitment and activation of immunosuppressive cells, such as regulatory T cells and myeloid-derived suppressor cells, and promote the infiltration of effector T cells into the tumor. Application of Cudarolimab Biosimilar Cudarolimab Biosimilar is being developed as a potential treatment option for various types of cancer, including solid tumors and hematological malignancies. It is currently in preclinical development, with plans for clinical trials in the near future. As a biosimilar, Cudarolimab Biosimilar offers a more affordable and accessible alternative to the originator antibody, Cudarolimab. This can potentially increase patient access to this targeted therapy and improve treatment outcomes. In addition, the unique mechanism of action of Cudarolimab Biosimilar, targeting the TNFRSF4 pathway, may offer a novel approach for the treatment of cancers that are resistant to current therapies. It also has the potential to be used in combination with other cancer treatments, such as chemotherapy and immune checkpoint inhibitors, to enhance their efficacy. Conclusion In summary, Cudarolimab Biosimilar is a promising therapeutic antibody that targets TNFRSF4, a key co-stimulatory molecule involved in T cell activation and survival. Its unique mechanism of action and potential for use in combination with other cancer treatments make it a promising candidate for the treatment of various cancers. With ongoing preclinical development and plans for clinical trials, Cudarolimab Biosimilar has the potential to make a significant impact in the field of cancer therapy.
Host
Reactivity
Applications
Conjugation
Cusatuzumab Biosimilar – Anti-CD70, TNFSF7 mAb – Research Grade, ProteoGenix, PX-TA1500
Description of Cusatuzumab Biosimilar - Anti-CD70, TNFSF7 mAb - Research Grade Cusatuzumab Biosimilar: An Anti-CD70, TNFSF7 mAb for Targeted Therapy Cusatuzumab Biosimilar, also known as anti-CD70 or TNFSF7 monoclonal antibody, is a research grade biologic drug that has shown promising results in the treatment of various cancers. This biosimilar is a replica of the original drug, Cusatuzumab, which was developed by the pharmaceutical company Novartis. The biosimilar version is being developed by various companies for its potential use as a more affordable and accessible alternative for patients. Structure of Cusatuzumab Biosimilar Cusatuzumab Biosimilar is a monoclonal antibody that specifically targets CD70, a protein found on the surface of cancer cells. It is a humanized IgG1 kappa antibody, meaning it is made up of human and mouse components to reduce the risk of immune reactions. The antibody has a molecular weight of approximately 150 kDa and consists of two heavy and two light chains, connected by disulfide bonds. The binding site of Cusatuzumab Biosimilar is located on the variable region of the heavy chain, which allows it to bind to CD70 with high specificity and affinity. This binding triggers a series of immune responses that ultimately lead to the destruction of cancer cells. Mechanism of Action The main therapeutic target of Cusatuzumab Biosimilar is CD70, a protein that is overexpressed in many types of cancer, including solid tumors and hematologic malignancies. CD70 is a member of the tumor necrosis factor (TNF) superfamily and plays a crucial role in the proliferation and survival of cancer cells. When Cusatuzumab Biosimilar binds to CD70, it blocks its interaction with its receptor, CD27, which is expressed on the surface of immune cells. This prevents the activation of the CD70-CD27 pathway, which is responsible for promoting cancer cell growth and survival. In addition, the binding of Cusatuzumab Biosimilar to CD70 also triggers the immune system to recognize and attack cancer cells, further enhancing its anti-tumor activity. Applications of Cusatuzumab Biosimilar The primary application of Cusatuzumab Biosimilar is in the treatment of cancer. It has shown promising results in preclinical and clinical studies for various types of cancer, including acute myeloid leukemia, multiple myeloma, and solid tumors such as renal cell carcinoma and non-small cell lung cancer. In addition to its use as a monotherapy, Cusatuzumab Biosimilar has also been studied in combination with other anti- cancer drugs, such as chemotherapy and immune checkpoint inhibitors. These combination therapies have shown synergistic effects and have the potential to further improve treatment outcomes for cancer patients. Conclusion Cusatuzumab Biosimilar is a promising biologic drug with a unique mechanism of action that specifically targets CD70, a protein involved in the growth and survival of cancer cells. Its potential as a more affordable and accessible alternative to the original drug makes it an attractive option for cancer treatment. With ongoing research and clinical trials, Cusatuzumab Biosimilar has the potential to become a valuable addition to the arsenal of anti- cancer therapies. Keywords: Cusatuzumab Biosimilar, anti-CD70, TNFSF7 mAb, monoclonal antibody, cancer, therapeutic target
Host
Reactivity
Applications
Conjugation
Dacetuzumab Biosimilar – Anti-CD40 mAb – Research Grade, ProteoGenix, PX-TA1166
Description of Dacetuzumab Biosimilar - Anti-CD40 mAb - Research Grade Introduction Dacetuzumab Biosimilar, also known as Anti-CD40 mAb, is a monoclonal antibody that targets the CD40 protein, a cell surface receptor involved in immune responses. This biosimilar version of Dacetuzumab has been developed for research purposes and has shown promising results in preclinical studies. In this article, we will discuss the structure, activity, and potential applications of Dacetuzumab Biosimilar as an antibody targeting CD40. Structure of Dacetuzumab Biosimilar Dacetuzumab Biosimilar is a recombinant, humanized monoclonal antibody that is produced in Chinese hamster ovary (CHO) cells. It has a molecular weight of approximately 150 kDa and is composed of two identical heavy chains and two identical light chains. The heavy chains consist of four constant domains (CH1, CH2, CH3, and CH4) and one variable domain (VH), while the light chains consist of two constant domains (CL and CL’) and one variable domain (VL). The variable domains of both the heavy and light chains form the antigen-binding site, which specifically recognizes and binds to the CD40 protein. Activity of Dacetuzumab Biosimilar The primary activity of Dacetuzumab Biosimilar is the inhibition of CD40 signaling. CD40 is a transmembrane receptor that is predominantly expressed on immune cells, such as B cells, dendritic cells, and macrophages. Upon binding to its ligand, CD40 activates various signaling pathways that play a crucial role in immune responses, including cell proliferation, survival, and differentiation. However, dysregulation of CD40 signaling has been linked to the pathogenesis of several autoimmune diseases and cancers. Dacetuzumab Biosimilar binds to CD40 with high affinity and blocks the interaction between CD40 and its ligand, thereby inhibiting downstream signaling and potentially modulating immune responses. Potential Applications of Dacetuzumab Biosimilar 1. Autoimmune Diseases Dacetuzumab Biosimilar has shown potential as a therapeutic option for autoimmune diseases, such as rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis. In preclinical studies, Dacetuzumab Biosimilar has been shown to reduce the production of pro-inflammatory cytokines and inhibit the activation of autoreactive T cells, which are key players in the development of autoimmune diseases. Furthermore, Dacetuzumab Biosimilar has been found to have a synergistic effect when combined with other immunosuppressive agents, making it a promising candidate for combination therapy. 2. Cancer CD40 has been identified as a therapeutic target for various types of cancer, and Dacetuzumab Biosimilar has shown potential as an anti- cancer agent. Preclinical studies have demonstrated that Dacetuzumab Biosimilar can induce cell death in cancer cells and inhibit tumor growth in animal models. It has also been found to enhance the activity of immune cells, such as T cells and natural killer cells, against cancer cells. These findings suggest that Dacetuzumab Biosimilar could be used as a monotherapy or in combination with other anti- cancer agents for the treatment of cancer. 3. Transplant Rejection Organ transplant rejection is a major concern in transplant medicine, and CD40 has been implicated in the rejection process. Dacetuzumab Biosimilar has been shown to inhibit the activation of immune cells that are responsible for transplant rejection, such as T cells and B cells. In addition, Dacetuzumab Biosimilar has been found to prolong the survival of transplanted organs in animal models. These findings suggest that Dacetuzumab Biosimilar could be used as an immunosuppressive agent to prevent transplant rejection. Conclusion Dacetuzumab Biosimilar, also known as Anti-CD40 mAb, is a monoclonal antibody that specifically targets the CD40 protein. It has a well-defined structure and inhibits CD40 signaling, making it a promising candidate for the treatment of autoimmune diseases, cancer, and transplant rejection. Further clinical studies are needed to evaluate the safety and efficacy of Dacetuz
Host
Reactivity
Applications
Conjugation
Daclizumab Biosimilar – Anti-IL2RA mAb – Research Grade, ProteoGenix, PX-TA1038
Description of Daclizumab Biosimilar - Anti-IL2RA mAb - Research Grade General information on Anti-IL2RA(Homo sapiens) (Daclizumab) Monoclonal Antibody Daclizumab is a humanized IgG1 monoclonal antibody that binds to human interleukin 2 receptor (anti-Tac or anti-CD25)and composed of human >90%) and murine (10%) antibody sequences. The human sequence is derived from the constant domain of human IgG1 and the variable framework region of Eu myeloma antibody. The murine part was taken from the complementarity-determining regions of a murine anti-Tac antibody. Daclizumab has been used for preventing acute organ rejection in de novo allogeneic kidney transplantation when used simultaneously with immunosuppressive regimens such as cyclosporine and corticosteroid and in the treatment of adult patients with relapsing multiple sclerosis. These trademarks were Zenapax and Zimbryta, respectively.
Host
Reactivity
Applications
Conjugation
Dalotuzumab Biosimilar – Anti-IGF1R, CD221 mAb – Research Grade, ProteoGenix, PX-TA1239
Description of Dalotuzumab Biosimilar - Anti-IGF1R, CD221 mAb - Research Grade Dalotuzumab Biosimilar: A Novel Anti-IGF1R Antibody for Targeted Cancer Therapy Dalotuzumab Biosimilar, also known as Anti-IGF1R, CD221 mAb, is a monoclonal antibody that specifically targets the insulin-like growth factor 1 receptor (IGF1R). IGF1R is a cell surface receptor that plays a crucial role in cell growth and proliferation, making it an attractive therapeutic target for cancer treatment. Dalotuzumab Biosimilar is a research-grade version of the original dalotuzumab, which has shown promising results in clinical trials as a potential cancer therapy. Structure of Dalotuzumab Biosimilar Dalotuzumab Biosimilar is a humanized monoclonal antibody, meaning it is derived from human antibodies and has been modified to reduce its immunogenicity. It is composed of two identical heavy chains and two identical light chains, connected by disulfide bonds. The antibody has a molecular weight of approximately 150 kDa and a half-life of 12-14 days in humans. The binding site of dalotuzumab biosimilar is located on the extracellular domain of IGF1R, specifically targeting the α-subunit of the receptor. This binding site has been designed to block the binding of IGF1 and IGF2, the natural ligands of IGF1R, thereby inhibiting the activation of downstream signaling pathways involved in cancer cell growth and survival. Mechanism of Action IGF1R is overexpressed in many types of cancer, including breast, lung, and colorectal cancer. This overexpression has been linked to increased cell proliferation, angiogenesis, and resistance to chemotherapy. By targeting IGF1R, dalotuzumab biosimilar aims to inhibit these processes and induce cancer cell death. Upon binding to IGF1R, dalotuzumab biosimilar blocks the interaction between the receptor and its ligands, preventing the activation of downstream signaling pathways such as PI3K/AKT and MAPK/ERK. These pathways are important for cell survival and proliferation, and their inhibition by dalotuzumab biosimilar leads to decreased cancer cell growth and increased apoptosis. Application of Dalotuzumab Biosimilar Dalotuzumab biosimilar is currently being evaluated in clinical trials for the treatment of various types of cancer, including breast, lung, and colorectal cancer. In a phase II clinical trial for metastatic colorectal cancer, patients who received dalotuzumab in combination with chemotherapy showed a significant improvement in progression-free survival compared to those who received chemotherapy alone. Furthermore, dalotuzumab biosimilar has also been studied in combination with other targeted therapies, such as cetuximab, in patients with advanced non-small cell lung cancer. The combination showed promising results, with a higher response rate and longer progression-free survival compared to cetuximab alone. Future Directions As dalotuzumab biosimilar continues to show promising results in clinical trials, it is expected to become an important addition to the arsenal of targeted cancer therapies. Its unique mechanism of action and potential for combination therapy make it a promising candidate for the treatment of various types of cancer. In addition, further research is being conducted to explore the potential of dalotuzumab biosimilar in other therapeutic areas, such as diabetes and growth disorders. Its ability to specifically target IGF1R makes it a potential candidate for the treatment of these diseases. Conclusion Dalotuzumab biosimilar, a novel anti-IGF1R antibody, has shown promising results in clinical trials as a potential cancer therapy. Its unique mechanism of action and potential for combination therapy make it a promising candidate for the treatment of various types of cancer. As research continues, dalot
Host
Reactivity
Applications
Conjugation
Daratumumab Biosimilar – Anti-CD38 mAb – Research Grade, ProteoGenix, PX-TA1213
Description of Daratumumab Biosimilar - Anti-CD38 mAb - Research Grade General information on Anti-CD38(Homo sapiens) (Daratumumab) Monoclonal Antibody Daratumumab is an immunoglobulin G1 kappa monoclonal antibody against CD38+ multiple myeloma cells.
Host
Reactivity
Applications
Conjugation
Please provide the required information below so that we can quickly source your products.